Sutro Biopharma Share Holder Equity 2017-2022 | STRO
Sutro Biopharma share holder equity from 2017 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Sutro Biopharma Annual Share Holder Equity
(Millions of US $) |
| 2021 |
$253 |
| 2020 |
$332 |
| 2019 |
$98 |
| 2018 |
$132 |
| 2017 |
$-6 |
| 2016 |
$12 |
Sutro Biopharma Quarterly Share Holder Equity
(Millions of US $) |
| 2022-03-31 |
$220 |
| 2021-12-31 |
$253 |
| 2021-09-30 |
$284 |
| 2021-06-30 |
$308 |
| 2021-03-31 |
$307 |
| 2020-12-31 |
$332 |
| 2020-09-30 |
$244 |
| 2020-06-30 |
$207 |
| 2020-03-31 |
$82 |
| 2019-12-31 |
$98 |
| 2019-09-30 |
$110 |
| 2019-06-30 |
$120 |
| 2019-03-31 |
$131 |
| 2018-12-31 |
$132 |
| 2018-09-30 |
$46 |
| 2018-06-30 |
$0 |
| 2018-03-31 |
$0 |
| 2017-12-31 |
|
| 2017-09-30 |
$0 |
| 2016-12-31 |
$12 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.246B |
$0.062B |
|
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
|
